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Abstract
Significance: Current lifestyles with high-energy diets and little exercise are triggering an alarming growth in
obesity. Excess of adiposity is leading to severe increases in associated pathologies, such as insulin resistance, type
2 diabetes, atherosclerosis, cancer, arthritis, asthma, and hypertension. This, together with the lack of efficient
obesity drugs, is the driving force behind much research. Recent Advances: Traditional anti-obesity strategies
focused on reducing food intake and increasing physical activity. However, recent results suggest that enhancing
cellular energy expenditure may be an attractive alternative therapy. Critical Issues: This review evaluates recent
discoveries regarding mitochondrial fatty acid oxidation (FAO) and its potential as a therapy for obesity. We focus
on the still controversial beneficial effects of increased FAO in liver and muscle, recent studies on how to potentiate
adipose tissue energy expenditure, and the different hypotheses involving FAO and the reactive oxygen species
production in the hypothalamic control of food intake. Future Directions: The present review aims to provide an
overview of novel anti-obesity strategies that target mitochondrial FAO and that will definitively be of high
interest in the future research to fight against obesity-related disorders. Antioxid. Redox Signal. 19, 269–284.
Obesity: Molecular and Pathophysiological Features
Obesity is defined as abnormal or excessive fat accu-mulation in the adipose tissue and other organs. The
World Health Organization (WHO) defines overweight as a
body mass index (BMI; calculated as weight [kg] divided by
height squared [m2]) equal to or greater than 25 kg/m2 and
obese as a BMI equal to or greater than 30 kg/m2 (137). Cur-
rent lifestyle trends and continuous nutrient excess are caus-
ing obesity to increase at alarming rates, especially in young
people. There are more than 500 million obese people
worldwide and, more importantly, overweight and obesity
are the fifth leading risk for death globally (137). Humanity is
facing a new epidemic already dubbed ‘‘Prosperity’s Plague’’
(160). Therefore, significant research is needed in the race to
find effective therapies and tominimize the enormous costs of
the related healthcare.
Weight gain is influenced by several factors, such as ge-
netics, maternal and perinatal environment, energy-dense
diets, and sedentary lifestyle (3). Of great concern are the
concurrent and parallel increases in the prevalence of patho-
logical conditions associated with obesity, which include in-
sulin resistance, type 2 diabetes, cardiovascular disease,
nonalcoholic fatty liver, polycystic ovary syndrome, asthma,
Alzheimer’s disease, and some forms of cancer. Elucidating
the causes involved in the pathophysiology of obesity-related
disorders is one of the most critical endeavors in modern
medical research.
Several mechanisms have emerged in the past two decades,
during which obesity and especially its connection to insulin
resistance have become a top-interest research topic being
studied by leading groups in the field.
Ectopic-fat deposition
When the adipose tissue cannot store excess fat, lipids ac-
cumulate inappropriately in the liver, muscle, and pancreas.
This lipotoxic environment, mainly mediated by diacylgly-
cerols (DAGs), blocks correct glucose transport and insulin
signaling (145). Thus, it has been postulated that any strategy
that could block the entry of fatty acids (FAs) into the cell,
promote fatty acid oxidation (FAO), or convert DAGs into
triglycerides (TGs) could prevent insulin resistance (160).
Inflammation
The pathophysiology of obesity-induced insulin resistance
has also been correlated with an increase in circulation and
tissue inflammation originating in the adipocyte damage and
infiltration of immune cells (107, 151). As fat accumulates in
adipose tissue, adipocytes overcome their healthy size limit
(157, 169) and release inflammatory cytokines and molecules
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known as adipokines. The excessive accumulation of lipids in
the adipose tissue leads to adipocyte hypoxia (73), en-
doplasmic reticulum (ER) stress (132), and cell death, and
causes FA spillover (145). Infiltrated immune cells also con-
tribute to this chronic low-grade inflammatory milieu,
whereby the increase in inflammatory cytokines causes in-
sulin resistance elsewhere in the body. Thus, anti-inflamma-
tory strategies become central as possible new treatments of
insulin resistance and other complications of obesity (56).
ER stress
The fundamental role of ER is the integration of multiple
metabolic signals and themaintenance of cell homeostasis (26,
58). Under stress conditions that challenge its function, ER
triggers an adaptive response called uncoupled protein re-
sponse (UPR) (97, 178). To resolve ER stress, UPR promotes a
decrease in protein synthesis, and at the same time, an in-
crease in protein degradation and chaperone production for
protein folding. During the chronic energy surplus associated
with obesity, ER cannot recover its normal function and UPR
activation contributes to the development of insulin resistance
through several mechanisms, such as JNK-Ap1 and NF-Kb-
IKK signaling pathways, inflammation, and oxidative stress (74).
Food intake
The central nervous system, specifically the hypothalamus,
is of crucial importance in obesity-induced pathologies, since
it plays a major role in the control of food intake and regu-
lation of body weight (177). The discovery of leptin was a
major breakthrough for our current knowledge of energy
homeostasis (179). This adipocyte-secreted hormone acts on
the hypothalamus to inhibit food intake and control body
weight and has proved essential in the interaction between the
brain and other organs in obesity-related disorders (51). The
alteration of the circadian rhythm has also been associated
with an increased risk of obesity (63, 76), proving that it is not
only what you eat, but also when you eat it. Thus, advances in
understanding the molecular mechanisms linking circadian
rhythms and metabolism may provide new therapies for
obesity and other pathologies associated with the disruption
of normal sleep–wake cycles.
Lack of Efficacy of Current Anti-Obesity Drugs
Obesity develops when energy intake exceeds energy ex-
penditure. Thus, any treatment for obesity-induced disorders
must reduce energy intake, increase energy expenditure, or
have an effect on both. Attempting to lose weight only by
caloric restriction comes up against the problem that mam-
mals have evolved mechanisms to store energy to survive
during periods of starvation. Such homeostatic mechanisms
increase caloric efficiency, thus making further weight loss
even more difficult. In recent years, several anti-obesity drugs
designed to limit energy intake have been withdrawn from
the market due to serious adverse effects (i.e., fenfluramine,
dexfenfluramine, sibutramine, and rimonabant) (36). Nowa-
days, only two drugs are approved specifically for weight loss
by the US Food and Drug Administration (FDA): the lipase-
inhibitor Orlistat that is also approved by the European
Medicines Agency (EMA), but has a limited long-term effec-
tiveness (36), and the recently approved serotonergic Lorca-
serin-Belviq (84, 126). Thus, more efforts are needed to
develop new anti-obesity agents. In this regard, strategies
designed to increase lipid mobilization and oxidation could
be very useful in the treatment of obesity and associated
diseases.
Mitochondrial FAO and Bioenergetics
Hormones, such as insulin, glucagon, and noradrenaline,
control the extracellular uptake and intracellular release of the
main cell fuels; namely, carbohydrates and FAs. Once inside
the cell, FAs are esterified, metabolized to lipid second mes-
sengers, or b-oxidized in mitochondria. The first step of the
oxidative pathway is the transport of long-chain FAs (LCFAs)
into the mitochondrial matrix (Fig. 1). This step is controlled
by the carnitine palmitoyltransferase (CPT) system, which
consists of three proteins: CPT1, acylcarnitine translocase
(CACT), and CPT2 (109). Malonyl-CoA, a molecule derived
from glucose metabolism and the first intermediate in lipo-
genesis, regulates FAO by inhibiting CPT1, thus making this
enzyme the rate-limiting step in mitochondrial oxidation of
FAs. Mammal tissues express three isoforms of CPT1: CPT1A
(41) (liver), CPT1B (175) (muscle and heart), and CPT1C (138)
(brain). Acetyl-CoA carboxylase (ACC), which controls the
synthesis of malonyl-CoA; malonyl-CoA decarboxylase
FIG. 1. Mitochondrial fatty acid oxidation (FAO). Long-
chain fatty acid (LCFA) catalysis implies activation by acyl-
CoA synthase (ACS) of LCFAs into LCFA-CoA, which is a
substrate for the mitochondrial carnitine palmitoyltransfer-
ase 1 (CPT1) enzyme. The CPT system, which includes CPT1,
acylcarnitine translocase (CACT), and CPT2, allows LCFA-
CoA to enter the mitochondrial matrix, via transesterification
reactions, to then be b-oxidized. CPT1 is the rate-limiting
enzyme in FAO since its activity is tightly regulated by the
glucose-derived malonyl-CoA, generated by acetyl-CoA
carboxylase (ACC) during fatty acid (FA) de novo formation
(in energetically abundant situations) or degraded by
malonyl-CoA decarboxylase (MCD) in a process regulated
by AMP-activated protein kinase (AMPK). Acetyl-CoA
generated in FAO eventually enters the tricarboxylic acid
(TCA) cycle to obtain reductive power for cellular respiration
and produce ATP. To see this illustration in color, the reader
is referred to the web version of this article at www
.liebertpub.com/ars
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(MCD), which catalyzes malonyl-CoA degradation; and
CPT1, which is regulated bymalonyl-CoA, are components of
a metabolic signaling network that perceives the level of fuel
stimuli (109).
One of the main regulators of this network is the AMP-
activated protein kinase (AMPK). This protein is the
downstream element of a kinase cascade, activated by its
phosphorylation in the Thr172 residue of the catalytic subunit
(174). In general, AMPK inhibits ATP-consuming processes,
while activating catabolic pathways. Active AMPK phosphor-
ylates and inhibits ACC and reduces the expression of FA
synthase, thus decreasing the flux of substrates in the FA ana-
bolic pathway (176). In consequence, the reduction in malonyl-
CoA levels leads to an increase in CPT1 activity and FAO.
The regulation of AMPK by members of the sirtuin fam-
ily of NAD + -dependent protein deacetylases and ADP-ribo-
syltransferases (sirtuins) has been reported (94). Sirtuin 1
(SIRT1) and SIRT3 stimulate AMPK by deacetylating its up-
stream activator, kinase LKB1 (94, 135). In turn, the AMPK
activity leads to an increase in NAD + levels, thereby pro-
moting deacetylation/activation of other SIRT1 targets
involved in FAO, like peroxisome proliferator-activated re-
ceptor c coactivator-1a (PGC-1a) (18). In recent years, sirtuins
have emerged as critical modulators of lipid metabolism and
specifically of FAO. In mammals, the seven identified mem-
bers of the sirtuin family are differentially located within the
cell: SIRT1, 6 and 7 are mainly located in the nucleus; SIRT3, 4
and 5 are located in the mitochondria; and SIRT2 is a cytosolic
protein (111). In specific tissues, sirtuins act on different
targets promoting FAO (liver and skeletal muscle [SkM]),
mitochondrial respiration (brown adipose tissue [BAT]),
lipolysis (white adipose tissue [WAT]), and food intake
(hypothalamus) (148).
Energy flow in living cells (bioenergetics) takes place
mainly in mitochondria. Energy is obtained from FAs and
other nutrients in the form of ATP—the chemical currency of
life—through the tricarboxylic acid (TCA) cycle, and the
electron transport chain (ETC) in a process known as oxida-
tive phosphorylation (162) (Fig. 2). This process is the main
source of reactive oxygen species (ROS) in the cell. In the ETC,
the energy of electrons from NADH and FADH2 is used to
pump protons (H + ) from the mitochondrial matrix to the in-
termembrane space and generate the electrochemical gradient
necessary for ATP synthesis. However, when these electrons
escape the ETC, ROS are produced in the mitochondria. Even
under physiological conditions, the incomplete electron
transfer to O2, resulting in ROS production, occurs with 0.2%–
2% of oxygen molecules (21). Mitochondrial ROS production
is highly regulated and important for various cell functions, as
ROS can act as signalingmolecules. However, high ROS levels
are associated with significant cell damage andmitochondrial
dysfunction in a process known as oxidative stress (122),
usually associated with the etiology of obesity, insulin resis-
tance, and type 2 diabetes (67).
In the mitochondria, the ETC complexes remain electron-
bounded when the proton gradient between the mitochon-
drial matrix and the intermembrane space is high, preventing
the outward pumping of H + and increasing ROS production.
Mitochondrial uncoupling proteins (UCPs) uncouple ATP
production from mitochondrial respiration, thereby reducing
the H + gradient across the inner mitochondrial membrane
and relieving the formation of ROS (106). In BAT, UCP1 dis-
sipates energy as heat and plays a key role in adaptive ther-
mogenesis. In other tissues, the UCP homologues (UCP2, 3,
and 4) affect ROS production and have crucial roles in energy
homeostasis (106).
The Central Role of Liver in Obesity
Fatty liver and nonalcoholic steatohepatitis
The liver plays a central role in both energy expenditure
and lipid/glucose homeostasis. In conditions associated with
prolonged excess of energy or impaired FA metabolism, the
liver stores considerable amounts of lipids in a process that
leads to nonalcoholic fatty liver disease (NAFLD). A hallmark
of NAFLD is the accumulation of hepatic TGs, which origi-
nate in the increased availability of free FAs (FFAs; circulating
and from de novo lipogenesis), altered FAO and inadequate
synthesis and export of VLDL (37, 55). The imbalance between
these inputs and outputs results in lipid accumulation in he-
patocytes, which causes hepatosteatosis and insulin resis-
tance. The progression of a more severe liver disease triggers
nonalcoholic steatohepatitis (NASH), a serious condition of
inflamed fatty liver that can further progress to liver fibrosis
and cirrhosis (32, 155). The pathogenesis of NAFLD in human
and animal models has been reviewed in seminal articles (27,
161). The mechanisms underlying NAFLD to NASH
FIG. 2. Bioenergetics and mitochondrial metabolism. The
mitochondrial fuels, glucose, and FAs, are converted to
acetyl-CoA, which can be further metabolized to obtain en-
ergy. The TCA cycle generates protons (H + ) and electrons
that are carried by NADH and FADH to the electron trans-
port chain (ETC), where the protons are transported to the
mitochondrial intermembrane (MIM) space to generate en-
ergy as ATP. Highly reactive electrons may leak from the
ETC and generate reactive oxygen species (ROS), which
could act physiologically as signaling molecules, but can also
cause significant cellular damage when overproduced. Un-
coupling proteins (UCPs) dissipate the proton gradient and
scavenge ROS accumulation, thus dissipating energy as heat.
To see this illustration in color, the reader is referred to the
web version of this article at www.liebertpub.com/ars
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progression are not completely understood. However, the
alteration of FA metabolism and ROS production, which lead
to mitochondrial dysfunction, and the induction of proin-
flammatory cytokines and fibrosis have emerged as key
components that ultimately cause this liver disease (47).
Alterations of mitochondrial FAO and ROS production
Mitochondria play a vital role in the oxidation of FAs and
ROS production. In the liver, mitochondrial FAO results ei-
ther in complete oxidation to carbon dioxide or in partial
oxidation to ketone bodies, which are exported to provide fuel
for other tissues. The key step is catalyzed by CPT1A (109).
Data on the rates ofmitochondrial FAO andCPT1A activity in
NAFLD/NASH are not conclusive, possibly because of the
use of different models and parameters. In vitro and in vivo
studies of liver or hepatocytes exposed to high FFA concen-
trations show both increased (25, 44, 112, 116) and decreased
(43) mitochondrial FAO. Similarly controversial results were
obtained with CPT1A expression and activity. An increase in
CPT1A expression has been reported in several rodentmodels
(14, 134). However, a considerable decrease in the expression
of this enzyme was observed in NAFLD patients (123). Sev-
eral mechanisms may explain these controversial data: (i) the
variation of malonyl-CoA levels that depend on the expres-
sion and activity of AAC/MCD enzymes (24, 39); (ii) the loss
of CPT1 sensitivity to malonyl-CoA, which alters CPT1 ac-
tivity (29, 133); and (iii) the increased pool of FFAs or lipid
derivatives in hepatocytes may activate transcription factors,
such as PPARs (PPARa, PPARb/d), which in turn may en-
hance CPT1 expression and FAO (19, 20, 22, 83). However, the
transcriptional effect of PPARa on liver CPT1 remains con-
troversial, since some studies have suggested that long-chain
FFA regulates CPT1 expression through a PPARa-independent
pathway (96, 101). Interestingly, another mechanism that
modulates the CPT1 activity has recently been proposed (150).
In this study, a NASH rat model fed a methionine-choline-
deficient diet had a notable reduction in CPT1A activity and
mitochondrial FAO despite increased CPT1A mRNA ex-
pression. The formation of a 4-hydroxynonenal-CPT1 adduct
caused by lipid peroxidation as a consequence of ROS over-
production is the main cause of impaired FAO and lipid re-
moval from hepatocytes. ROS can attack polyunsaturated
FAs, initiating lipid peroxidation and the formation of alde-
hyde by-products (ahydroxy-2-nonenal [HNE] and mal-
ondialdehyde [MDA]), which have longer half-lives than ROS
and are able to spread from their site of origin to reach distant
intracellular and extracellular targets, thereby amplifiying the
effects of oxidative stress (44, 170). The observations listed
above suggest that CPT1 overexpression and increased CPT1
activity occur in liver during the onset of steatosis as a
mechanism to compensate for increased FA levels. Ac-
celerated mitochondrial FAO might cause excessive electron
flux in the ETC and ROS overproduction. As lipids, proteins,
and mitochondrial DNA are the main ROS targets, increased
ROS might initiate lipid peroxidation, damage mitochondrial
DNA and proteins, and alter mitochondrial morphology and
function. The post-translational modifications of CPT1 caused
by lipid peroxidation could, subsequently, decrease CPT1
activity and reverse initially activated FAO. This notion raises
the question of whether interventions aimed at promoting
mitochondrial FAO in liver would be beneficial to the treat-
ment of NAFLD/NASH.
Several strategies have been used to promote FAO, in-
cluding the use of PPAR agonists (7, 114), AMPK agonists
[metformin (180), AICAR (166)], and ACC antagonists (62,
108). Genetic aproaches specifically promoting liver FAO are
of considerable interest. An improvement in high-fat diet
(HFD)-induced liver insulin resistance has been described in
rodents, in which, FAO was indirectly enhanced by the re-
duction of malonyl-CoA levels through the modulation of
ACC (146) and MCD (4). More interesting are the results ob-
tained with a direct enhancement of mitochondrial FAO by
increasing CPT1A expression in liver. Recent studies (117,
130) overexpressing an active and malonyl-CoA-insensitive
mutant form of CPT1A (CPT1AM) (118) in obese rodents
show that permanently enhanced liver FAO not only rescues
impaired hepatic, muscle, andWAT insulin signaling in these
animals, but also reduces steatosis, inflammation, and adi-
posity (Fig. 3). Furthermore, in these studies, enhanced
FIG. 3. Effects of enhanced
FAO in fatty liver. (A) Obe-
sity increases FA uptake, tri-
glyceride (TG), diacylglycerol
(DAG), ceramides, and other
lipid derivatives that may
inhibit insulin signaling. FA
accumulation induces mito-
chondrial dysfunction and
increased ROS production,
oxidative stress, and inflam-
mation that could also dis-
rupt insulin signaling. (B)
Enhancing FAO by the over-
expression of CPT1AM (117,
130) increases the production
of ketone bodies, ATP, and
CO2. The reduction of lipid
content re-establishes lipid
metabolism, insulin signal-
ing, and decreases inflam-
mation and ROS production.
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mitochondrial FAO did not increase ROS derivatives or liver
injury. Taken together, these results highlight an increase of
CPT1A as a new strategy for the treatment of NAFLD/NASH
pathologies. Alternatively, it has been reported that the ad-
mistration of CPT1 inhibitors reduces gluconeogenesis and
improves glucose homeostasis, although chronic treatments
on HFD-treated mice caused hepatic steatosis (28, 53). This
side effect has interrupted the development of other systemic
inhibitors, such as etomoxir and 2-tetradecylglycidic acid, as a
therapeutic tool. Taken together, these data support the idea
that any strategy able to switch liver FA’s fate from esterifi-
cation toward oxidation produces a beneficial effect on the
liver and on the whole body. It seems that the liver can deal
with an increased flux of FA into the mitochondria, thus es-
caping from liver injury. This is due to the ability of liver to
flip the balance from complete oxidation to ketone body
production (88). The ketone bodies produced by enhanced
FAO are easily consumed by other tissues, increasing the flux
of carbons from liver to other organs. Recently, a new hepatic
factor, fibroblast growth factor 21 (FGF21), has emerged as a
key regulator in FAO and ketogenic activation. FGF21 is
induced in the liver during fasting (136) and has been
increasingly pointed to as a potential therapeutic agent in
obesity-induced insulin-resistant states (78).
WAT Meets Inflammation and Metabolic
Disorders in Obesity
WAT has long been recognized as the main storage site for
lipids derived from food intake (142). This long-term energy
reservoir stores lipids mainly in the form of TGs, which can be
mobilized and used to generate ATP through the mitochon-
drial b-oxidation pathway in peripheral organs during peri-
ods of caloric need.
WAT is composed mainly by adipocytes, but also by im-
mune cells, such as macrophages, T cells, and mast cells (68,
104). Thus, WAT is an active and endocrine organ that se-
cretes a large number of adipokines, cytokines, and chemo-
kines (i.e., leptin, adiponectin, resistin, TNFa, IL-6, MCP-1,
and IL-10), and plays a key role in regulating whole-body
glucose and lipid metabolism (46, 151).
WAT, obesity, and inflammation
Obesity is characterized by the expansion of WAT mass
due to an increase in both adipocyte number (hyperplasia)
and size (hypertrophy), and it is closely associated with in-
sulin resistance in peripheral tissues, such as SkM and liver. In
fact, under excess caloric intake, WAT reaches its upper limit
for further lipid storage (157, 169). Consequently, adipocytes
exceed their oxygen diffusion limit, thereby promoting hyp-
oxia (73), ER stress (132), and cell death, and increased cir-
culating FFA and TG accumulation in ectopic sites is
produced (145). The combination of microhypoxia and lipid
overload triggers the recruitment of immune cells, such as
macrophages in the adipose tissue and their activation (103,
129, 171). Obese adipocytes and infiltrated immune cells se-
crete a large amount of inflammatory mediators that promote
a proinflammatory state through the activation of IKKb-NF-
Kb and the JNK-Ap1 signaling pathways (151). The induction
of JNK leads to serine phosphorylation of IRS-1 and 2, crucial
molecules in insulin signaling, and consequently inhibits in-
sulin action. These events cause insulin resistance in adipo-
cytes, exacerbation of the inflammatory state, and systemic
insulin resistance (59, 147) (Fig. 4).
FFAs, inflammation, and ROS
Physiological ROS production in adipocytes is a relevant
cellular signaling mechanism in the insulin response and it
depends mainly on the NADPH oxidase (NOX) family ac-
tivity (9). In obesity, the excess of FFAs increases NOX-
mediated ROS generation. Recently, it has been demonstrated
that increased ROS in adipocytes exposed to an excess of FFAs
does not depend on enhancedmitochondrial flux, but on high
levels of TNFa and ER stress as well as the upregulation of
aforementioned NOX enzymes (8, 60). ROS have the capacity
to interfere with insulin signaling, since they activate several
downstream pathways involving MAPK, JNK/IKKb, and
FIG. 4. White adipose tis-
sue (WAT), obesity, and in-
sulin resistance. Nutrient
overload, weight gain, and
obesity result in increased
adipose tissue mass and adi-
pocyte size. The expansion of
the adipose tissue leads to
adipocyte hypoxia, death,
and free fatty acid (FFA) re-
lease into circulation. These
events trigger the recruitment
and activation of immune
cells, such as macrophages
and T cells, in the adipose
tissue. Infiltrated and acti-
vated immune cells and adi-
pocytes secrete large amounts
of proinflammatory cyto-
kines, which promote the in-
hibition of insulin signaling
with an ensuing local and
systemic resistance (147).
LIPIDS, FATTY ACID OXIDATION, OBESITY 273
JAK/STAT, which are key contributors to the development of
insulin resistance in obesity and type 2 diabetes (8, 75).
Enhanced FAO and improvement in insulin sensitivity
The imbalance between lipid storage and lipid utilization
predisposes to adipocyte dysfunction and FFAs promote the
proinflammatory response and ROS production involved in
severe metabolic disorders. Although the exact physiological
role of FAO in WAT remains to be determined, recent studies
have shown beneficial effects of increased FAO and lipolysis
in adipocytes, through direct CPT1A overexpression. In fact,
this rise in lipid utilization improves insulin sensitivity in
these cells and suppresses inflammatory signaling (50).
However, there is still no evidence that increasing adipose
tissue FAO would decrease FFA-induced ROS production.
Thus, further research is required to elucidate these mecha-
nisms and to evaluate the potential benefit of this strategy to
prevent or reverse obesity and related metabolic diseases.
BAT, Turning Up the Heat
BAT morphology and function
In addition to energy-storing WAT, human fat consists of
thermogenic controlling BAT. The latter has traditionally re-
ceived less attention than WAT since it is less abundant and
was considered exclusive to rodents and children. However,
more recently, BAT have gained relevance in the mechanisms
involved in obesity-related disorders.
BAT thermogenesis takes place in its numerous, densely
packed mitochondria, which contain the BAT-specific UCP1.
Activation of this protein uncouples aerobic respiration by
producing heat instead of ATP (162). Brown adipocytes are
also differentiated from white adipocytes because of their
high expression of type 2 iodothyronnine deiodinase (DIO2),
the transcription coregulators, PRDM16 and PGC-1a, and the
lipolytic regulator, Cidea (52, 131). In rodents, BAT generates
heat mainly for two reasons; namely, to protect against cold
exposure via nonshivering thermogenesis and to burn the
excess calories and reduce fat accumulation (54, 72). There-
fore, BAT plays a crucial role in protecting mice from diet-
induced obesity.
Rediscovery of human BAT
The fusion of positron emission tomography (PET) and
computed tomography (CT) images allowed radiologists to
see both functional and structural information in a single
image. In the course of using PET-CT to detect and stage tu-
mors in humans, active BAT was observed to increase after
cold exposure (124).
However, the real breakthrough arrived in 2009 when five
independent groups used PET-CT to identify the presence
and study the relevance of BAT in adult humans (30, 143, 165,
168, 181). All the groups showed major depots of metaboli-
cally active fat in the cervical–supraclavicular region, a
slightly different site from that in rodents and children, where
BAT is found mainly situated in the interscapular area. The
expression of UCP1, DIO2, and the b3-adrenergic receptor
was also reported, thereby indicating the potential respon-
siveness of human BAT to both hormonal and pharmaco-
logical stimuli.
Interestingly, human studies showed that BAT is reduced
in obese and diabetic patients, thus indicating that this tissue
participates in both cold-induced and diet-induced thermo-
genesis (30). These observations made BAT a major break-
through, since any strategy able to increase the mass or
activity of this tissue could potentially provide hope for obese
and diabetic patients.
BAT bioenergetics and mitochondrial metabolism
BAT is the only tissue to express UCP1, a protein found in
the inner mitochondrial membrane that orchestrates the un-
coupled reaction of allowing protons to re-enter the mito-
chondrial matrix without generating ATP. The dissipation of
energy as heat confers BAT with the capacity to control
thermogenesis. In fact, altered UCP1 expression (UCP1-
deficient or transgenic mice) leads to dysregulated sensitivity
to cold exposure and body weight control (40, 42, 86, 87, 98).
Body temperature changes stimulate norepinephrine re-
lease by sympathetic nervous endings that activate b-
adrenergic receptors and trigger a signal transduction cascade
that converts nutrients into acetyl-CoA. The TCA cycle uses
this mitochondrial fuel to produce protons and electrons,
which generate ATP through the ETC. However, in BAT,
UCP1 allows protons to enter the mitochondrial matrix
without generating ATP, that is, uncoupled, and heat is pro-
duced in this process. Thus, BAT burning power intensely
clears and oxidizes circulating lipids and glucose to generate
heat (17). This observation thus highlights BAT thermogen-
esis as an attractive therapeutic anti-obesity target.
Enhancing BAT burning power and browning
of WAT as an anti-obesity strategy
Recent landmark studies have identified novel secreted
proteins, such as liver FGF21 (72), cardiac natriuretic peptides
(11), and irisin (12), that stimulate brown adipocyte thermo-
genesis. Interestingly, a moderate increase (threefold) in irisin
blood levels in mice enhanced energy expenditure and im-
proved obesity and glucose homeostasis (12). In addition,
recent articles reported that macrophages (125) and the bone
morphogenetic protein BMP8B (172) have also the capacity to
regulate BAT thermogenesis. Therefore, promoting BAT ac-
tivation and/or brown adipocyte recruitment in white fat
(browning) are approaches of considerable interest by which
to develop pharmacological strategies to improve systemic
metabolism by increasing energy expenditure (Fig. 5).
Role of FAO in Muscle Insulin Sensitivity During Obesity
SkM is vital for the maintenance of glucose homeostasis. It
accounts for *80% of total glucose uptake after insulin
stimulation (34) and its transition to an insulin-resistant state
is central for the pathogenesis of type 2 diabetes (152). Various
pathways trigger obesity-induced insulin resistance (147).
Both the action of fat-derived cytokines (adipocytokines) and
ectopic accumulation of lipid deposition impair SkM function
and play a critical role in insulin sensitivity. Obesity is char-
acterized by a greater breakdown and uptake of FAs. Parallel
with the increase in circulating lipids, the intramyocellular
(IMC) lipid content appears to increase proportionally in ob-
ese humans (105) and rodents (23). The lipotoxic hypothesis
proposes that FAs and their metabolites (such as DAG and
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ceramides) are important contributors to lipid-induced insu-
lin resistance in SkM. These molecules activate proin-
flammatory and nutrient-sensing pathways that lead to the
impairment of insulin action (Fig. 6A) [for further informa-
tion, readers are referred to additional reviews (144, 159)].
Muscle FAO in obesity: two sides of the same coin
Several strategies have been designed to prevent IMC lipid
accumulation and its deleterious effects. In SkM, these are
mainly focused on the inhibition of FA uptake and esterifi-
cation and/or the increase in FAO. However, whether the
metabolic shift toward fat oxidation ameliorates lipid-
induced SkM dysfunction is still open to debate.
Different laboratories have demonstrated that a decrease in
the size and number of mitochondria, the activity of proteins
in the ETC and, in general, impaired oxidative capacity in
SkM are associated with obesity and insulin resistance in
humans and animals (102, 139, 153). Given these observa-
tions, it is postulated that increased mitochondrial FAO could
prevent lipid accumulation and, thus, improve insulin sensi-
tivity in SkM (Fig. 6B). Several lines of evidence support this
idea: (i) exercise in obese humans increases muscle mito-
chondrial FAO and improves glucose tolerance and insulin
sensitivity (16). This effect is probably due to increased CPT1
expression and activity during exercise (163); (ii) direct CPT1
overexpression in animals and SkM cells protects muscle from
FA-induced insulin resistance and apoptosis (15, 66, 149); and
(iii) indirect SkM CPT1 activation, by the use of AMPK acti-
vators (77) or the ACC2 knockout (1), ameliorates insulin-
stimulated glucose uptake in rodents.
Despite all the above points, the idea of mitochondrial de-
ficiency as the main cause of diet-induced insulin resistance
has been challenged in recent years. First, it is known that
SkM’s capacity to oxidize substrates is far in excess of what is
needed to supply the energy demands of resting muscle (5).
With this in mind, it seems clear that the mild (&30%) re-
duction in mitochondrial content observed in obese patients
does not affect the ability of resting muscle to oxidize fat.
Further, despite the reduction in the mitochondrial content,
insulin-resistant SkM has normal mitochondrial function (13).
Secondly, since FA and glucose compete as metabolic sub-
strates, the decrease in FAOwould produce enhanced glucose
utilization instead of insulin resistance. In fact, patients with
severe mitochondrial deficiency have an increase in glucose
uptake despite the large accumulation of IMC lipids (61). And
finally, a HFD causes insulin resistance in rodents, while in-
ducing an increase in SkM mitochondrial biogenesis and b-
oxidation (164). This suggests that FAO might already be
enhanced during obesity, contributing to the development of
insulin resistance (121).
The main problems associated with an increase in FAO are:
(i) the high rates of incomplete fat oxidation and (ii) the in-
crease in oxidative stress associated with a mitochondrial
overload (Fig. 6C) (89). Koves et al. (89) postulated that HFD
induces the expression of FAO-related genes, but not those
associated with the ETC and TCA cycle. This causes a mis-
match between FAO and TCA cycle activity, thus leading to
the accumulation of incomplete FAs and other intermediates
(i.e., acylcarnitines) that correlate negatively with glucose
tolerance (2). How these intermediates mediate the onset of
insulin resistance is still unknown. However, studies linking
overnutrition with the acylation of mitochondrial proteins are
relevant to this topic and suggest a role for acylcarnitines (70).
Mitochondrial members of the sirtuin family are known to
deacetylate/activate several proteins involved in fat oxida-
tion. This along with the observation that SIRT3 knockout
mice have high acylcarnitines and increased acylated mito-
chondrial proteins and develop metabolic syndrome, implies
that mitochondrial accumulation of FAO intermediates trig-
gers metabolic complications via protein modification (71, 80).
Role of ROS in muscle insulin signaling
FAO intermediates may also create an unfavorable envi-
ronment in the mitochondria, which contributes to the for-
mation of ROS and the development of oxidative stress (119,
120). High levels of ROS and systemic oxidative stress have
been associated with obesity and insulin resistance (45).
However, these molecules are produced normally during
mitochondrial respiration and are essential signal transducers
that regulate several cell processes in SkM (8), including the
insulin pathway (64, 65). Due to its dual role in insulin sen-
sitivity, modulation of redox balance is crucial for correct cell
function. On the one hand, under physiological conditions,
ROS are generated in response to insulin and are required for
its action (69), since the activity of different enzymes that
participate in the insulin cascade are dependent on their oxi-
dation state. In particular, the phosphatases that negatively
modulate the insulin pathway are the main targets for oxi-
dative inhibition by ROS (35). It has also been reported that
ROS enhance insulin sensitivity in HFD mice (100). These
molecules are also crucial for the SkM remodeling that occurs
in response to exercise (31). ROS show insulin-like effects,
stimulating SkM glucose uptake during muscle contraction
via the activation of AMPK (81) and the induction of PGC-1a
FIG. 5. Stimulation of
brown adipose tissue (BAT)
thermogenesis. Cold expo-
sure, exercise, and some se-
creted proteins, such as
fibroblast growth factor-21
(FGF-21) (72) and irisin (12),
enhance BAT burning power
by promoting brown adipo-
cyte recruitment in white fat
(browning).
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expression in vitro and in vivo (57, 79). On the other hand,
during a pathophysiological state, abundant evidence indi-
cates that a large and sustained increase in ROS impairs in-
sulin action, through the activation of stress signaling
pathways (i.e., MAPK and JNK) (85, 154), contributing to the
pathogenesis of diet-induced insulin resistance (67). There-
fore, clarifying the role of mitochondrial FAO, and the ROS
production derived from it, in diet-induced SkM insulin-re-
sistance is crucial to the development of new therapeutic
strategies to fight against obesity and its related metabolic
complications.
Hypothalamic FAO in the Regulation of Food Intake
Excess food intake in obesity is related to behavioral pro-
cesses controlled by the central nervous system. Specific hy-
pothalamic nuclei, which sense nutrients and modify energy
intake and expenditure to maintain a balance, are responsible
for regulating this intake (48). Themechanisms for sensing the
nutritional state have not been fully discovered and less is
known about lipid than glucose sensing. Nonetheless, there
are two classic hypotheses on nutritional state metabolic
mediators, involving malonyl-CoA and LCFA-CoA.
CPT1A on food intake control: linking the malonyl-CoA
and LCFA-CoA hypotheses
Strong evidence shows that increased malonyl-CoA levels,
which are generated by activated (i.e., dephosphorylated)
ACC, act as abundance indicators, thereby diminishing food
intake and consequently body weight (173). During starva-
tion, ACC phosphorylation is mainly controlled by the well-
known energy sensor, AMPK (115), which acts also as an
important hub, integrating in-cell energetic state sensing and
its modulation due to different circulating hormones. Con-
cretely, ghrelin-mediated activation (i.e., phosphorylation) of
AMPK is done via SIRT1-mediated activation (i.e., deacetyla-
tion) of p53. It is known that the SIRT1 activity is increased in
hypothalamus during starvation with high ghrelin levels
(167). The mechanism of leptin action also appears to be re-
lated to increases in physiological malonyl-CoA in the arcuate
nucleus, which promotes a reduction in food intake and body
weight, using different mechanisms to those previously re-
ported for ghrelin action, during energetically wealthy states
(49, 141).
In addition, LCFA-CoA levels have also been put forward
as mediators in nutritional state sensing. During starvation,
circulating FFA increase can be sensed in hypothalamic nuclei
through in-cell activation to LCFA-CoA. This increase, pre-
vious to active ghrelin rise, is an early reporter of a deficient
nutritional state (156). However, unfortunately, no cytoplas-
mic LCFA-CoA increase in hypothalamus has been found.
Even so, in the last decade, pharmacological and genetic in-
hibition of hypothalamic CPT1A has been reported to reduce
the food intake (10, 110, 127), potentially as a result of LCFA-
CoA cytoplasmic accumulation. Furthermore, the role of
malonyl-CoA as a CPT1 inhibitor is worth noting, to link the
two hypotheses.
Regardless of whether malonyl-CoA or LCFA-CoA is the
main actor, changes in feeding behavior and peripheral me-
tabolism are conducted via the action of neuropeptides, such
as agouti-related protein (AgRP), neuropeptide Y (NPY), and
melanocortins. Transcription factors affected by changes in
hypothalamic FAO, such as CREB, FoxO1, and BSX, are
involved in ghrelin-induced expression of NPY and AgRP
(92). However, it is still unknown whether high levels of
LCFA-CoA trigger NPY and AgRP via BSX and subsequent
transcription factors. Probably, neither malonyl-CoA nor LCFA-
CoA act as key molecular mediators per se to induce the ex-
pression of the different food intake-controller neuropeptides,
FIG. 6. Two hypotheses for the role of FAO in the de-
velopment of obese-induced insulin resistance in skeletal
muscle (SkM). (A) During obesity, intramyocellular lipid
accumulation leads to a decrease in insulin-stimulated glu-
cose uptake in SkM (144). (B) An increase in FAO may de-
crease LCFAs, ceramide, and DAG content, thus enhancing
insulin action (15, 66, 149). (C) However, an increase in FAO
may augment ROS production and enhance the accumula-
tion of products of incomplete b-oxidation (PIO), which are
hypothesized to decrease insulin signaling through the acti-
vation of various stress kinases (89).
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but they are just two of the several pieces involved in the
highly complex hypothalamic nutritional state sensing sys-
tem, which is still not fully understood.
The relevance of FAO in neuronal cells is controversial
because glucose is the brain’s primary energy source. How-
ever, basal levels of FAO enzymes and FA transport proteins
(such as FATP-1, FATP-4, and FAT/CD36) are expressed in
hypothalamic neurons (93, 95). Additionally, the presence of
such small, but functional FAO could be explained by its es-
sential role in neuronal FA turnover and its action as a lipid-
sensing mediator for energy homeostasis (113). There is also
another controversy regarding fasting, because during fast-
ing, high blood FFA levels presumably reach hypothalamic
nuclei. This does not fit in with the satiety effect observed in
early experiments with high LCFA concentration in the hy-
pothalamus (128). Nonetheless, the direct correlation ob-
served between fasting and FFA levels (156) and the capacity
of hypothalamic neurons to sense glucose and FFA simulta-
neously and to integrate other nutritional and hormonal in-
puts (95, 99) seem to throw light on how important FAO really
is in hypothalamic nuclei.
ROS, third in discord
Along with malonyl-CoA and LCFA-CoA, mitochondrial
ROS have been put forward as a mediator in response to
nutrient availability (140) (Fig. 7). ROS in the hypothalamus
are produced chiefly in mitochondria ECT complexes. Con-
cretely, some authors pointed to complex I as the most rele-
vant site for single electron reduction in brain mitochondria
(90). Various kinases and transcription factors, involved in
neuropeptide regulation, have been reported to bemodulated
by redox signaling (33, 91). Further, the signaling under dif-
ferent levels of ROS may imply dissimilar pathophysiological
changes in proteins, depending on their redox state (33). A
certain level of ROS, without being excessive, is probably re-
quired to trigger neuropeptide expression. This notion may
explain the importance of UCP2 as a ROS scavenger to keep a
physiological ROS level that allows correct NPY and AgRP
expression in the hypothalamus (6). In addition to all these
considerations, the recent finding that hypothalamic autop-
hagy is a source of endogenous FFA to regulate AgRP levels
(82) could be explained by increased mitochondrial FAO and
ROS signaling. However, further research is needed to es-
tablish the contribution of ROS to the hypothalamic control of
food intake.
Innovation
Recent results suggest that enhancing cellular energy ex-
penditure may be an attractive therapy to prevent or reverse
the exponential growth of obesity-related disorders. We re-
viewed those recent discoveries regarding mitochondrial
FAO and its potential as a therapy for obesity.
Conclusions
Despite considerable current efforts, the prevalence of
obesity and associated diseases is rising exponentially in both
industrialized and developing countries worldwide. This is
especially worrying in the young. Current therapeutic strat-
egies, focused mainly on controlling food intake, have met
limited success, probably due to the inherent resistance of the
human body to weight loss. However, recent approaches
targeting energy expenditure and mitochondrial FAO shed
light on new therapies to fight obesity.
Mitochondrial FAO is the cell source of energy from FAs.
Since an excess of lipids is found in obesity and associated
pathologies, a lot of research studies how to eliminate them
through an increase in FAO. Beneficial effects of an increase in
energy expenditure in obesity have been described in several
tissues, including liver, muscle, WAT, and BAT. On the con-
trary, FAO therapeutic inhibition in hypothalamus seems to
reduce food intake.Whether or not FAO should bemodulated
in the above-mentioned tissues to improve insulin resistance
or to lose weight is still a subject of debate. There is no doubt
regarding the involvement of ROS in pathophysiological
processes related to obesity, and CPT1 seems to be a good
molecular target for ROS and FAO modulation. However,
several questions still need to be answered before FAO can
become an obesity therapy. First, it is not known whether a
long-term increase in energy expenditure would cause an
enhancement of appetite as a compensatory mechanism.
Second, an increase in FAO could induce pathological levels
of ROS and/or other incomplete oxidation products. Third, it
is not known whether FAO enhancement might reach a limit
in a specific tissue, such as in BAT, in which thermogenesis is
tightly adjusted to the environmental temperature. Finally,
since increasing flux through b-oxidation would only make
sense together with a corresponding enhancement in energy
demand (121), the physiological relevance of improved mi-
tochondrial FAO might be questioned if the individual re-
mains sedentary (muscle, WAT, or liver) or warm (BAT).
Potential mechanisms to explain the beneficial effects of tar-
geting mitochondrial FAO could be the concomitant en-
hancement of hepatic ketone bodies, CO2, acid soluble
products, ATP production, and endergonic processes (e.g.,
gluconeogenesis) seen in previous publications (38, 130, 158).
FIG. 7. Hypotheses involving FAO in the regulation of
food intake. During fasting, the effects of ghrelin, AMP, and
FAs act in hypothalamic nuclei to increase the expression of
orexigenic neuropeptides (48). The mechanisms involved in
this process appear to be related to an increase in LCFA-
CoA, diminished malonyl-CoA, and a certain level of ROS.
Excessive ROS production is controlled by UCP2 with a
negative feed-back. CPT1A is postulated to be involved in all
the three approaches.
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Increased FAO may also decrease glucose oxidation to
maintain energy homeostasis, augment mitochondrial burn-
ing capacity through an increase in the number of mito-
chondria and/or the increased expression of UCPs, and thus
dissipate the excess of energy as heat and ATP. All of these
could well alleviate the mitochondrial pressure found in lipid
overload states. Thus, an increase in energy expenditure could
indeed be the underlying protective mechanism against obe-
sity-induced metabolic abnormalities.
Although more research is needed, we are encouraged that
targeting of FAO and cell energy expenditure may be avail-
able in the near future as therapies to treat obesity and its
associated severe diseases.
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ACC¼ acetyl-CoA carboxylase
AgRP¼ agouti-related protein
AMPK¼AMP-activated protein kinase
BAT¼ brown adipose tissue
BMI¼ body mass index
CACT¼ acylcarnitine translocase
CPT1¼ carnitine palmitoyltransferase 1
CPT1A¼ liver CPT1
CT¼ computed tomography
DAG¼diacylglycerol
ETC¼ electron transport chain
FA¼ fatty acid
FAO¼ fatty acid oxidation
FAS¼ fatty acid synthase
FFA¼ free fatty acid
FGF21¼fibroblast growth factor 21
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IMC¼ intramyocellular
LCFA-CoA¼ long-chain fatty acid-CoA
MCD¼malonyl-CoA decarboxylase
NAFLD¼nonalcoholic fatty liver disease
NASH¼nonalcoholic steatohepatitis
NPY¼neuropeptide Y
PET¼positron-emission tomography
ROS¼ reactive oxygen species
SkM¼ skeletal muscle
TCA¼ tricarboxylic acid
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UCPs¼uncoupling proteins
UPR¼uncoupled protein response
WAT¼white adipose tissue
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